Company Focus
Takeda
Latest Takeda News
Biotechnology
Licensing of innovator oligonucleotide drugs for central nervous system (CNS) indications surged 339% in 2024, jumping from $640 million to $2.81 billion, according to research from GlobalData. 24 June 2025
Related News
Insights
Company Spotlight
An American biotech company developing solutions that treat urothelial and specialty cancers.
Latest News & Features of interest to Takeda
Pharmaceutical
US biopharma Vertex Pharmaceuticals and Japanese drugmaker Ono Pharmaceutical have announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. 23 June 2025
Pharmaceutical
Swiss drugmaker Idorsia today announced that Simcere Pharmaceuticals (HK: 2096) has received approval for Quviviq (daridorexant) from the Chinese National Medical Products Administration for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep, with no psychotropic drug control labeling. 23 June 2025
Biotechnology
Swiss pharma giant Roche has released encouraging results from the Phase III SUNMO study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin), delivered a seismic update in aggressive lymphoma therapy. 23 June 2025
Pharmaceutical
Armed with an asset that could be an improvement on Pfizer’s blockbuster smoking cessation drug Chantix/Champix (varenicline), Achieve Life Sciences (Nasdaq: ACHV) has confidence in its prospects of addressing the global smoking health and nicotine addiction epidemic. 23 June 2025
Pharmaceutical
Notable research news last week included Sarepta Therapeutics reporting another death associated with a trial of its Duchenne muscular dystrophy drug Elevidys. On the M&A front, US pharma major Eli Lilly last Tuesday announced it is to acquire Verve Therapeutics for up to $1.3 billion, along with its VERVE-102. Regulatory news saw the US Food and Drug Administration (FDA) announce a new voucher program aimed at enhancing the health interests of Americans. The FDA also approved Incyte’s Monjuvi for relapsed or refractory follicular lymphoma (LF). 22 June 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hetronifly (serplulimab) to treat adults with extensive-stage small cell lung cancer (ES-SCLC), which has not previously been treated, and has spread within the lungs or to other parts of the body. 21 June 2025
Pharmaceutical
US healthcare group Abbott has signed a wide-ranging agreement with health authorities in Abu Dhabi to localize pharmaceutical manufacturing, develop biosimilars, and accelerate digital transformation, as the emirate deepens its bid to become a regional powerhouse in the global life sciences sector. 20 June 2025
Biotechnology
Danish vaccine specialist Bavarian Nordic is set to collect $160 million from the sale of a US priority review voucher (PRV) earned through the approval of its chikungunya vaccine, Vimkunya (chikungunya vaccine), marking one of the highest prices paid for a PRV in recent years. 20 June 2025
Pharmaceutical
Japan’s Ministry of Health, Labor and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to include adults aged 18 to 49 years at increased risk of severe RSV disease. 20 June 2025
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval at its June 2025 meeting. 20 June 2025
Latest In Brief for Takeda
Biotechnology
The benefits from Eli Lilly’s Kisluna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute for Health and Care Excellence (NICE), which also rejected Japanese drugmaker Eisai and US biotech Biogen Leqembi (lecanemab) for the same reason. 19 June 2025
Latest Relevant Ones To Watch News
Notable research news last week included Sarepta Therapeutics reporting another death associated with a trial of its Duchenne muscular dystrophy drug Elevidys. On the M&A front, US pharma major Eli Lilly last Tuesday announced it is to acquire Verve Therapeutics for up to $1.3 billion, along with its VERVE-102. Regulatory news saw the US Food and Drug Administration (FDA) announce a new voucher program aimed at enhancing the health interests of Americans. The FDA also approved Incyte’s Monjuvi for relapsed or refractory follicular lymphoma (LF). 22 June 2025
16 June 2025
12 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze